



REVIEW ARTICLE

Phytochemical, pharmacological and tissue culture studies of some important species of the genus *Barleria* L. (Acanthaceae) - a review

Sudheer WN & Praveen N*

Department of Life Sciences, CHRIST (Deemed to be University), Bengaluru 560 026, Karnataka, India

*Email: praveen.n@christuniversity.in

ARTICLE HISTORY

Received: 03 February 2021

Accepted: 18 May 2021

Available online: 01 July 2021

KEYWORDS

Acanthaceae

Metabolites

Flavonoids

Barlerin

Iridoid glycosides

ABSTRACT

Ayurvedic sciences helped the early humans to overcome chronic dangerous diseases. There are thousands of varieties of herbs and medicinal plants used to overcome such dreadful diseases. The genus *Barleria* L. belongs to family Acanthaceae, a medicinally significant group of plants having diversified phytochemicals used for different pharmacological properties. It has been utilized since ancient times for medicinal purposes. It has many plant secondary metabolites such as terpenes, flavonoids, lignins, alkaloids, particularly the iridoid glycosides. The secondary metabolites extracted from *Barleria* spp. show potential pharmacological activities viz., anti-microbial, anti-inflammatory, anti-oxidant, anti-fertility, anti-arthritis and anti-ulcer activity. In view of these, present review is focused on the phytochemistry, pharmacology and tissue culture studies of some of the important species of the genus *Barleria* L.

Introduction

Since ancient time, mankind has depended on plants for his food, shelter, clothing and medicines. The science of Ayurveda allows us to become familiar with plants and their medicinal properties. The genus *Barleria* L. belongs to the family Acanthaceae and there are many reports proving the medicinal properties of this genus. A total of 300 species have been reported globally, mainly distributed throughout the Asia, South Africa and most of the tropical countries (1). Numerous phytochemicals reported from various species of *Barleria* which are responsible for medicinal properties (2). The *Barleria* species are usually seen as herbs or shrubs with simple leaves which are usually arranged in decussate manner and few species have sharp apex. They have diverse coloured tubular flowers with epipetalous stamens, arranged in solitary, axillary and cymes. Thorns/spines are present at the axial positions, which are modified bracts (3). In ayurvedic medicine, *Barleria* species are used for their anti-fertility, anti-diabetic, cytoprotective, immunoprotective properties (4). Especially, Iridoid glycosides which are present in *Barleria* play a major role in building up the pharmacological profile. In this review, we have discussed about the phytochemicals, pharmacological activities and plant tissue culture studies of some important species of genus *Barleria*.

Phytochemistry of *Barleria* species

Macroscopic and microscopic studies on *Barleria* helps us to understand the chemical compositions present in the plant body right from leaves, stem and roots. There are many pharmacologically active compounds present in the plant body of *B. prionitis*. The decoctions of the *B. prionitis* leaves reveal the presence of metabolites like alkaloids, tannins and oils. Tannins are also present in the bark of *B. prionitis* (5). Glycosides like scutellarein 7-rhamnosylglucoside, is reported in *B. prionitis* (6). Acetyl Barlerin A with molecular formula $C_{21}H_{28}O_{13}$ and Barlerin B with molecular formula $C_{19}H_{26}O_{12}$ are isolated and compared with the standard spectroscopic data and they are found to be iridoids isolated from *B. prionitis* (7). Later, Barlerin is also reported to be present in the methanolic extract of *B. dinteri* (8). From the ethanolic extracts of *B. prionitis*, a compound known as Balarenone was isolated. Spectral studies helped to find the molecular formula as $C_{29}H_{34}O_5$ (9). The gum fraction extracted from the ethanolic extract of the *B. prionitis* showed the presence of Barlerinoside, which is a phenylethanoid glycoside. Spectral data revealed that the molecular formula of the compound is $C_{41}H_{56}O_{24}$ with chemical name $\beta(3,4\text{-dihydroxyphenyl})\text{-ethyl-}\alpha\text{-L-rhamnopyranosyl-(1'''\rightarrow3''')-\alpha\text{-L-rhamnopyranosyl-(1''}\rightarrow3'')\text{-}\beta\text{-D-glucopyranosyl-(1''}\rightarrow6'')\text{-4-O-(3,4-dihydroxycinnamoyl)-}\beta\text{-D-glucopyranoside}$ (10).

In *B. lupulina* the aerial parts are subjected to metabolite analysis using ethanol and hexane. During chromatography technique, CH₂Cl₂-methanol at ratio of (80:20) fractions showed presence of shanzhiside methyl ester along with Barlerin (8-O-acetylshanzhiside methyl ester) and Acetyl Barlerin (6,8-O,O-diacetylshanzhiside methyl ester) which are chief iridoid glucosides present in *Barleria* spp. (11). In aerial parts of *B. lupulina*, minor iridoid compounds like ipolamiidoside and 6-O-acetylshanzhiside methyl ester are isolated and they are characterised using spectroscopic analysis (12). Compounds like 6-O-p-methoxy-cis-cinnamoyl-8-O-acetylshanzhiside methyl ester, 6-O-p-methoxy-trans-cinnamoyl-8-O-acetylshanzhiside methyl ester, 6-O-p-cis-coumaroyl-8-O-acetylshanzhiside methyl ester and 6-O-p-trans-coumaroyl-8-O-acetylshanzhiside methyl ester are isolated from leaves of *B. lupulina* (13). In the flowers of *B. lupulina* lupilinoside is isolated which is an iridoid diglucoside. Chemically it is 8-O-acetyl-2'-O-(β-glucopyranosyl) mussaenoside with molecular formula C₂₅H₃₈O₁₆ (14). In the ethanolic extract of *B. lupulina*, iridoid glycosides like 8-O-acetylpolamiidic acid, 8-O-acetyl-6-O-(p-methoxy-cis-cinnamoyl)shanzhiside and 8-O-acetyl-6-O-(p-methoxy-trans-cinnamoyl)shanzhiside were isolated and iridoid rich component having other active compound showed potent alkaline phosphatase activity (15). Spectral analysis conducted on the aerial extracts from *B. lupulina* showed the presence of chakyunglupulins A and B, which are the 4,8,8-trimethylcyclooct-2-enone derivatives. The molecular formula of chakyunglupulin A and B was found to be C₁₁H₁₈O₄ (16). In the aqueous extract of *B. lupulina*, 4-ethylcatechol, 4-vinylcatechol and 4-methylcatechol were isolated (17). The ethanolic extracts from *B. lupulina* showed the presence of Barlupulins, which are iridoid glycosides. NMR spectroscopic observations reveal that Barlupulin A has molecular formula C₂₀H₂₈O₁₃, Barlupulin B has molecular formula with C₂₂H₃₀O₁₄, and Barlupulin C, D has the same molecular formula C₁₇H₂₄O₁₂ (18). Another iridoid glycoside namely Barlupulin C methyl ester was isolated from aerial parts of *B. lupulina*. NMR data suggests that the molecular formula of the compound is C₁₈H₂₆O₁₂ (19). Compounds like cyclobutane, 1,1-dimethyl-2-octyl, 1-Hentetracontanol, 1,2-Benzenedicarboxylic acid, diisooctyl ester, 1-Hentetracontanol, 2-Hexyl-1-octanol were isolated from the essential oils of *B. lupulina* (20).

In *Barleria buxifolia* Linn., roots were subjected to benzene extraction and it is seen that pigments like Barleriaquinone. The molecular weight and chemical formula of Barleriaquinone is found to be 238.0659 and C₁₅H₁₀O₃. Spectroscopic studies help us to understand that the chemical name of the isolated quinone is 1-hydroxy-7-methylanthroquinone (21). Spectroscopic analysis helps us to find out that different compounds are present in *B. strigosa*. Strigoside is a compound isolated having a chemical name 4-hydroxyphenylethyl 4-O-β-D-glucopyranosyl-(1→3)-O-α-L-rhamnopyranoside with molecular formula C₂₀H₃₀O₁₁ and another iridoid compound with chemical name 10-O-trans-coumaroyl-eranthemoside with molecular formula C₂₄H₂₈O₁₁ (22). From the

methanolic extracts of *B. strigosa* parvifloroside A and B were isolated, which are phenylethanoid glycosides. The molecular formula of parvifloroside A and B is found to be C₂₉H₃₆O₁₅, these compounds show great anti-oxidant properties (23).

From the ethanolic extracts of *Barleria trispinosa* an iridoid compound is isolated with molecular formula C₂₅H₃₈O₁₆ having chemical name 6-α-L-rhamnopyranosyl-8-O-acetylshanzhiside methyl ester, which is illustrated using NMR spectroscopy (24). In *Barleria acanthoides* there are diversified compounds isolated from the n-butanol extracts. Spectral analysis suggests the presence of compounds called Barleriside A and B. Molecular formula of the isolated compounds are C₂₁H₂₀O₁₀ and C₂₉H₃₅O₁₅. Chemical name of the Barleriside A is found to be 8,4'-dihydroxy-6-O-(β-D-glucopyranosyl)flavone and Barleriside B is 1-O-caffeoyl-6-(3',4'-dihydroxyphenyl)ethyl-O-α-L-rhamnopyranosyl-(1→3) β-d-glucopyranoside (25). In the n-butanol subfraction of methanolic extract from *B. acanthoides* showed presence of neolignan diglycoside called Barlericin. High resolution fast-atom bombardment mass spectroscopic results suggested that the molecular formula of the isolated Barlericin is C₃₁H₄₀O₁₅ (26). Mixture of 4-hydroxy-trans-cinnamic acid alkyl esters and oleanolic acid (triterpene compound) were isolated from the methanolic extract of *Barleria cristata* (27). The list of important phytochemicals present is represented in Table 1.

Analytical methods for standardization of phytochemicals in *Barleria* species

Development of validated analytical methods is very important to analyse the phytochemicals in the polyherbal extracts. Chromatographic techniques were employed to screen the biochemicals in the plant extracts of *Barleria*. Important metabolites like Barlerin, Acetylbarlerin and Shanzhisidemethylester from *Barleria* spp. were analysed using HPTLC. It is seen that mobile phase having chloroform-ethylacetate-methanol-acetic acid at concentration of 3:3:3:1 showed best results at 233 nm. Upon statistical data analysis it was seen that highest content of barlerin was found in the shoot regions of *B. prionitis*. Acetylbarlerin is found highest in the leaves of *B. lupulina* and Shanzhisidemethylester content is found highest in leaves of *B. prionitis* (31). HPTLC and RP-HPLC methods were developed for *B. cristata*. An optimised HPTLC technique was developed with the help of solvent system having methanol: ethyl acetate: toluene: formic acid at (1: 1: 7.5: 0.2) to separate and quantify the significant anti-oxidants like quercetin, apigenin and naringenin at 308 nm. In RP-HPLC method, potassium dihydrogen phosphate along with methanol at 30:70 was used as solvent system and the detection of biochemicals was done at 330 nm. These standardised analytical methods helped in evaluating the phytochemical markers in plasma (32). Various saponins were identified in the leaf extracts of *B. cristata*. It is seen that in the optimised mobile phase having chloroform: glacial acetic acid: methanol: water at 6.4:3.2:1.2:0.8 ratio was used for analysis. Anisaldehyde-sulphuric acid reagent is used to obtain the chromatogram and later saponins were analysed from plates at 500 nm (33).

In *B. prionitis*, HPTLC technique was developed to quantify the various biochemicals. Saponins were analysed with optimized solvent system having chloroform: glacial acetic acid: methanol: water at ratio of 6.4:3.2:1.2:0.8. Chromatograms were compared with gallic acid, and it is seen that extracts showed presence of tannins. Flavonoids were qualitatively estimated using ethyl acetate: formic acid: glacial acetic acid: water at 10:1.1:1.1:2.6 ratio as solvent system. It is seen that leaf showed the highest percentage in the presence of saponins, tannins and related metabolites when compared to roots (34). GC-MS analysis was employed to analyse the biomolecules present in different extracts of *B. buxifolia* L. and *B. montana*. A total of 26 compounds were analysed which comes under broader class of flavonoids, alkaloids, terpenoids and tannins from ethanolic extract of *B. montana*. It is seen that injector at 280 °C and helium gas with the flow at 0.8 ml/min is used in improved protocol (35). Similarly in *B. buxifolia*, 30 compounds were analysed from methanolic extract of leaf. It is seen that injector at 230 to 250 °C and helium gas with the flow at 1ml/min was used in improved protocol (36).

Pharmacology of *Barleria* species

Anti-viral property

Cytopathic effect assay is conducted against respiratory syncytial virus (A2 strain) using 6-O-cis-p-coumaroyl-8-O-acetylshanzhiside methyl ester and 6-O-trans-p-coumaroyl-8-O-acetylshanzhiside methyl ester and it is found that 1:3 ratio of the cis and trans isoforms of above mentioned compounds isolated from *B. prionitis* showed best half maximal inhibitory concentration (IC₅₀) and half best maximal effective concentrations (EC₅₀) at 42.2 µg/ml and 2.46 µg/ml respectively (37). Plaque inhibition assay suggest that the anti-viral activity of *B. lupulina* extracts against Herpes simplex virus type 2 strain G, and some medical isolates of HSV-2 is very much promising and its activity is compared with *Clinacanthus nutans* which is also an Acanthaceae member. It is seen that *C. nutans* anti-viral activity is not up to the mark when compared to *B. lupulina*. Yield reduction assay also suggests that *B. lupulina* has promising viricidal effects (38).

Anti-fertility activity

Methanolic root extracts of *B. prionitis* reduced the fertility in male rats. It is seen that administration of 100 mg/l concentration of the plant extracts obstructed the spermatogenesis in rats. Anatomical studies helped to understand that the spermatids, cross sectional area of sertoli cells and leydig cells drastically reduced. Fertility tests conducted on male rats proved the anti-fertility effect of *B. prionitis* (39, 40). In northern Thailand folk medicine, *Barleria* species are used in anti-fertility and when a study conducted on wistar male rats proved that *B. strigosa* played significant role in inducing hormonal imbalance and ultimately reducing the sperm count and making rats infertile (41). Different fractions of crude methanol extract from *B. prionitis* root were eluted with 3:1 and 1:1 concentrations of trichloromethane with methanol. The fertility ability of the treated individuals decreased rapidly and the

parameters like sperm motility, spermatogenic cells count and biochemical parameters like total protein, sialic acid and glycogen content were drastically changed in treated rats. Fraction eluted with 1:1 ratio of trichloromethane with methanol showed best results (42).

Anti-inflammatory activity

B. lupulina is used as anti-inflammatory agent and its extracts are used as antidote for snake poison (43). Methanolic extracts of leaves and shoots of *B. lupulina* showed best anti-inflammatory activity against carrageenan and serotonin induced paw oedema and the extract showed results which are equal to that of indomethacin, which is a standard drug at 300 mg/kg concentration which is ideal (44). Another study was carried out on different animal models having carrageenan induced paw oedema and ethyl phenylpropiolate induced ear oedema. Myeloperoxidase activity (for neutrophil migration), trypan blue exclusion and MTT cytotoxicity assays demonstrates that methanolic extracts from *B. lupulina* showed best anti-inflammatory activities (45). Alkyl catechols, which are present in hot aqueous extracts of *B. lupulina* are found to be playing an important role in activating Nrf2 defence pathway which ultimately helps the organism in overcoming the inflammation (17). The pharmacologically active components having iridoid glucosides in the aqueous fraction (TAF) of *B. prionitis* showed best results with respect to anti-inflammation. The study was carried on different sets of rats which have induced the inflammation using carrageenan, histamine and dextran. Treatment of these effected rats with TAF fraction showed comparable results with respect to standard drugs like Ibuprofen. Leucocyte migration inhibition assay also suggested that TAF fraction of *B. prionitis* taken from methanol extract showed best results (46). Membrane stabilization activity and mast cell protection activity is studied after the administration of hydro alcoholic extracts of *B. prionitis* in rats. It is seen that ethanolic extract at 10 µg/ml concentration showed best results with respect to membrane stabilization and it is comparable to that of indomethacin, standard drug at 10 µg/ml concentration. The percentage of degranulation of mast cells is monitored and it is seen that 10 µg/ml concentration showed best results against the toxicant compound 48/80 (47). Carrageenan induced paw oedema model is established and effect of the anti-inflammatory activity of methanolic extract from *B. prionitis* is estimated. It is seen that methanolic extract at 500 mg/kg concentration showed best efficiency in reducing the inflammation (48). 8-O-acetyl shanzhiside methyl ester, shanzhiside methyl ester rich component from *B. prionitis* showed inhibition against myeloperoxidase, matrix metalloproteinase-9 and elastase enzymes and release of cytokines which prove the anti-inflammatory activity (49).

The effect of *B. cristata* leaf extracts on carrageenan induced paw oedema, acetic acid induced vascular permeability and castor oil induced diarrhoea was studied and it was seen that 500 mg/kg concentration of the extract showed best results in

inhibiting the oedema, inhibited the vascular permeability. Indomethacin is used as a standard drug at 10 mg/kg in all studies (50). Leaves of *B. cuspidate* are studied for their wound healing property. The methanolic fractions at 10% w/w and 15%w/w concentrations were used for the study. It was seen that these fractions showed best results with respect to wound healing (i.e., decrease in the wound length) and comparable to that of the nitrofurazone which is the standard drug (51). Formalin at the concentration of 0.1 mg/kg is administered to the albino Wistar rats to induce the inflammation. It is seen that leaf ethanol extracts from *B. montana* at 300 mg/kg body weight concentration reduced the inflammation. The blood biochemistry parameters like levels of haemoglobin, red and white blood cells were also taken into consideration and the efficiency is compared with indomethacin at 25 mg/kg body weight concentration (52).

Neuroprotectivity activity

Methanolic extracts of *B. lupulina* are studied for their neuro-pharmacological activity in mice, which are induced by propylene glycol. General behaviour tests for sound response, touch and pain responses are conducted on different sets of mice and rats. Along with these muscle relaxant tests like traction test, rotarod performance tests, 30° inclined tests are conducted. It is seen that in all the above tests conducted, on overall *B. lupulina* extracts show promising pharmacological activity when compared to standard neuroleptics (53).

Anti-oxidant activity

DPPH radial scavenging activity suggest that the availability of the anti-oxidant molecules are present in the methanolic extracts of whole *B. prionitis* and from the leaf extracts of *B. greenii*, as they showed ideal half maximal effective concentration. The efficiency is compared with that of ascorbic acid which is a strong anti-oxidant (54). The antioxidant property of the ethanolic extracts from *B. prionitis* helped in reversing the cataract which is induced with the help of galactose and selenite at 25 moles/kg body weight concentration. Ethanolic extract at 200 mg/kg and 400 mg/kg body weight concentration showed best results in reducing the oxidative stress (55). Ferric thiocyanate method and thiobarbyturic acid methods also suggest that the ethanolic extract from *B. prionitis* have promising anti-oxidant activity (56). Ferrous reducing power, DPPH radial scavenging activity, nitric oxide radical scavenging activity, hydrogen peroxide radical scavenging activity, superoxide anion scavenging activity and ABTS⁺ radical cation decolourisation assay were conducted on leaf and root extracts of *B. noctiflora* and root extracts showed best results and performed best anti-oxidant activity (57). The ethanolic extracts from *B. cristata* were checked for their anti-oxidant activity. DPPH assay, ABTS⁺ assay and FRAP assay were conducted to check the efficiency of the ethanolic extracts. It is seen that ethanolic extracts showed best results in all conducted assays and it is compared with that of butylated hydroxyl toluene (BHT) which is a standard anti-oxidant (58). DPPH

radical scavenging assay, nitric oxide radical scavenging assay was conducted on ethanolic extracts of *B. gibsonii*. The results suggest that the presence of pharmacologically significant anti-oxidant molecules which showed their efficiency in scavenging the DPPH radicals which was compared with standard anti-oxidant molecule, ascorbic acid. And scavenging of nitric oxide radicals from sodium nitroprusside were also seen which ultimately proved their promising anti-oxidant activity (59).

Immuno-protective activity

Immuno-protectivity of the methanolic extracts from *B. lupulina* was proved with the help of checking the parameters like WBC count, spleen WBC count, spleen weight and delayed type hypersensitivity reaction on footpad thickness. It is seen that 600 mg/kg concentration of the extract showed good results along with 300 mg/kg (60). Oral administration of the iridoid fraction of the methanolic extract from *B. prionitis* triggered the immune response in the rats. Different tests like neutrophil adhesion test, haemagglutinating antibody titre test, delayed type hypersensitivity response test, cyclophosphamide-induced immunosuppression test and macrophage phagocytosis by carbon clearance test were conducted to check the efficiency of the extracts. It is proved that shanzhiside methyl ester and barlerin rich iridoid component helps in immunomodulation (61).

Anti-cancer activity

The cytotoxicity effect of the *Barleria* quinones (Barleriaquinone-I, Barleriaquinone-II) isolated from *B. buxifolia* roots are studied and it is seen that Barleriaquinone-II showed best LD₅₀ when compared to Barleriaquinone-I in human breast adenocarcinoma cells (MCF7) (62). The anti-cancer activity of the methanolic extracts from *B. grandifolia* were studied against cancer cell lines i.e., A- 549 (human lung cancer) cells, Dalton's lymphoma ascites. Methanolic extracts showed best half-maximal inhibitory concentration against dalton's lymphoma ascites with the value 137.2 µg/ml. Various parameters like tumor weight, viable cell count, tumor volume were taken into consideration and the methanolic extracts showed best anti-tumour activity (63).

Anti-arthritis activity

B. lupulina from the ancient days is used for treating arthritis. Scientifically it is proved that methanolic extracts from the leaves showed promising activity against arthritis. Study was carried out on different animal models of induced arthritis like formalin-induced arthritis, collagen type II-induced arthritis, monosodium iodoacetate induced osteoarthritis. It is seen that at 300 mg/kg and 600 mg/kg concentrations of the administered extracts showed comparable promising anti-arthritis activity with that of indomethacin at 10 mg/kg concentration (60). Artificially arthritis is induced using chemicals like formaldehyde and freund's adjuvant (FCA) in the sprague-dawley rats. It is seen that ethanolic extracts of *B. prionitis* leaves showed decreased arthritis score and paw volume which was increased as a sign of

arthritis. Ethanolic extract of concentration 250 mg/kg showed best results with respect to all tests conducted. The efficiency of anti-arthritic activity is checked with the standard drug, diclofenac at 4 mg/kg body weight concentration (64).

Anti-Ulcer activity

Aerial parts (Leaves, shoot regions) of *B. lupulina* were subjected to methanolic extraction and their anti-ulcer properties are studied. It is seen that in pylorus ligated rats the methanolic extract of *B. lupulina* at 200 mg/kg concentration showed promising anti-ulcer activity and the results are comparable with famotidine at 30 mg/kg which is the standard anti-ulcer drug. The effect of *B. lupulina* extracts on different animal models where ulcer is induced using stress, alcohol and Indomethacin. It is seen that methanolic extracts of *B. lupulina* showed best results in alcohol induced stress even when compared with famotidine and omeprazole (65). Aspirin at 200 mg/kg concentration, ethanol at 1 ml/200 mg concentration with respect to body weight is administered to induce ulcer in rats. Iridoid fraction from *B. prionitis* at 200 mg/kg body weight concentration showed best efficiency in reducing the ulcers. Cold-restraint stress and pylorus ligated induced ulcer models were also developed and the activity of the iridoid fraction on them is checked. Many parameters like acid output, pH value and gastric juice amount were taken into consideration. It is concluded that *B. prionitis* extracts which are rich in iridoid fraction have promising anti-ulcer activity (66). In pylorus ligated induced ulcer, the efficiency of ethanolic extracts from *B. gibsoni* was checked for its anti-ulcer property. It is seen that acidity levels and ulcer lesions got reduced upon the administration of 500 mg/ml concentration of the extracts and its capacity to reduce ulcer lesions is compared with omeprazole at 20 mg/ml concentration.

Anti-diabetic activity

In the streptozotocin induced diabetic rats the anti-diabetic activity of the methanolic extracts of *B. lupulina* is studied and it was found that at 300 mg/kg body weight concentration showed decreased amount of glucose content in the blood and showed comparing efficiency with Glibenclamide at 10 mg/kg body weight concentration (67). In another study, animals were induced with alloxan monohydrate at 150 mg/kg concentration and ethanolic extracts of *B. prionitis* were administered. It is seen that ethanolic leaf extracts showed potent anti-diabetic activity and showed the reduced glucose levels by increasing the serum insulin levels when compared to root extracts (68). Ethyl acetate fraction from the ethanolic extract of *B. noctiflora* showed promising *in-vitro* and *in-vivo* anti-diabetic activity. The anti-diabetic property was compared with glibenclamide at 10 mg/kg. The ethyl acetate fraction showed reduced glucose levels in the blood which was isolated from high fat diet fed and streptozotocin induced diabetic rats at 40 mg/kg body weight concentration (69). The ability of inhibiting the α -amylase and α -glucosidase enzymes by ethanolic and petroleum ether extracts of *B. cristata* leaves proved its anti-diabetic activity. It is seen that

100 μ l concentration of both extracts showed promising efficiency (70).

Hepatoprotectivity

In *B. prionitis* its iridoid rich fraction was used to study the hepatoprotectivity. The study is carried out on different rat models which are liver toxicated with drugs like carbon tetrachloride (100 μ l/kg), galactosamine (300 mg/kg) and paracetamol (200 mg/kg). The median lethal dose of the drug in oral administration and intraperitoneal administration is studied. Serum parameters (alkaline phosphatase, alanine transaminase, aspartate transaminase) and hepatic parameters (lipid peroxidation) are taken into consideration for the study and this rich fraction of *B. prionitis* is proved to have hepatoprotectivity (71). The methanolic extracts of *B. montana* leaves were administered in the liver damaged rats and the serum enzyme parameters were analysed. It is seen that methanolic extracts at 500 mg/kg concentration successfully inhibited the enzyme levels of serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) and the efficiency is compared with silymarin which is standard drug against liver disorders. Anatomical studies at tissue level also suggested that *B. montana* has capacity to repair the damaged liver tissues (72). Another study was carried out on liver damaged animal model which is caused with the help of carbon tetrachloride. It is seen that methanolic extracts from the aerial parts of *B. montana* at the concentration of 400 mg/kg and 800 mg/kg reduced the serum sensitive enzymes levels for the liver damage i.e., serum glutamic oxaloacetic transaminase, serum glutamic pyruvic transaminase, alkaline phosphatase (73).

Anti-bacterial property

Compounds like Balarenone, pataline, 13,14-seco-stigmasta-5,14-diene-3- α -ol which were isolated from the crude extract of *B. prionitis* showed anti-bacterial property especially against *Bacillus cereus* (ATCC 14579) and *Pseudomonas aeruginosa* (ATCC 27853) (9). Different types of plant extracts using soxhlet apparatus were developed from the dried leaves of *B. prionitis*; among them ethanolic extract at 10 mg/ml showed best anti-bacterial activity against *Staphylococcus aureus* followed by *Salmonella typhi*, *Vibrio cholera*, *Escherichia coli* (74). Different fractional extracts made out of hexane and ethyl acetate from *B. prionitis* showed anti-bacterial activity (75). Different solvent extracts like methanol, ethanol, chloroform, di-chloromethane, acetone and water of *B. montana* Nees are studied for their anti-bacterial property. Anti-bacterial study is carried out on species like *Bacillus subtilis*, *Streptococcus pneumoniae*, *Staphylococcus aureus*, *Escherichia coli*, *Salmonella typhi*, *Pseudomonas aeruginosa*, *Klebsiella pneumoniae* and *Proteus vulgaris*. It is seen that acetone extracts showed best anti-bacterial property in the decreasing order against *Pseudomonas aeruginosa*, *Escherichia coli* and *Salmonella typhi*. The efficiency is compared with the standard drug streptomycin (76). The efficiency of the methanolic extracts of *B. montana* at 100 mg/ml and 200 mg/ml concentration were tried on different species of

gram-positive bacteria like *Bacillus subtilis*, *B. cereus*, *B. pumilis*, *Staphylococcus aureus* and gram-negative bacteria like *Escherichia coli*, *Pseudomonas aeruginosa*, *P. vulgaris*, *Serratia marcescens*. It is seen that the efficiency was moderate and that is compared with 10 µg/ml chloramphenicol, which is the standard drug (73). The essential oil extracted from *B. lupulina* having many important phytochemicals like cyclobutane, 1,1-dimethyl-2-octyl, 1-Hentetracontanol, 1,2-Benzenedicarboxylic acid, diisooctyl ester, 2-Hexyl-1-octanol showed its antibacterial affect against the species like *Bacillus pumilus* and *Staphylococcus aureus* (20).

Anti-fungal activity

Minimum inhibitory concentration and minimum fungicidal concentrations of the extracts of petroleum ether, dichloromethane from *B. albostellata* showed best results against *Candida albicans* (ATCC 10231). In the same way the ethanolic extracts of *B. greenii* leaves showed highest minimum inhibitory dilution and proved its fungicidal activity and that efficiency is similar to that of its root and stem which ultimately helps the harvesters to go with plant part substitution to replace the less available parts (54). Methanolic extract of *B. montana* at concentration of 100 mg/ml and 200 mg/ml showed moderate anti-fungal activity against fungal species like *Aspergillus niger*, *Rhizopus stolonifer*, *Sacharomyces cerevisiae* and *Penicillium chrysogenum*. The efficiency is compared with that of 10 µg/ml nystatin (73). Hot water extracts from the aerial parts of *B. grandiflora* showed promising antifungal activity against *A. fumigatus*. It is seen that the extracts down regulated the metabolic pathways which are very much important for the survival and pathogenicity of the *A. fumigatus* (77). Natural dye extracted from aerial parts of *B. prionitis* showed anti-fungal activity against species like *A. flavus*, *A. niger*, *A. parasiticus*, *Fusarium moniliforme* and *Penicillium canescens*. The minimum inhibitory concentration of the natural dye against the mentioned fungal species ranges like 23.25, 22.75, 23.5, 22.5 and 23 µg/ml. The fabrics which are made out of this natural dye is recommended for textile purposes (78).

Anti-diarrhoeal activity

Iridoid glycoside component isolated from *B. prionitis* was studied for its anti-diarrhoeal activity. Different tests like PGE2-induced enteropooling, charcoal transit test was conducted and it is seen that iridoid component successfully inhibited the enteropooling and fluid transition. 100 mg/kg concentration of the extract inhibited the castor oil induced diarrhoea and the efficiency is compared with loperamide, which is a standard drug (79).

Anti-hypersensitive activity

Methanolic extract of the leaves of *B. prionitis* is employed for studying the anti-hypersensitive activity. Hypersensitivity is induced in the rat with the help of Deoxycorticosterone acetate (DOCA) salt at the concentration of 20 mg/kg body weight. It was observed that methanolic extract at 400 mg/kg showed best results in reducing hypertension (80).

Marketed medicinal formulations from *Barleria* spp.

Barleria species are used in formulation of herbal toothpastes. Vicco vajradanti (81) is a herbal toothpaste made from *B. prionitis*, which have capacity to reduce the salivary glucose and pH. It is also seen as a chief ingredient in Patanjali Dantkanti (82). *B. prionitis* is the chief component in Sahacharadikashayam, an ayurvedic polyherbal formulation which is used as an anti-oxidant (83). Whole plant is of *B. prionitis* is used in the polyherbal formulation of Maharasnadikwath. This liquid extract showed great anti-arthritis potential with anti-oxidant activity (84).

Tissue culture Studies in *Barleria* spp.

Biotechnological approach helped the mankind to solve his problems in effective manner. Tissue culture is one of such biotechnological tool which helped to conserve the medicinal plant species and their medicinally important metabolites. *Barleria* species being threatened in the wild, there is an immense requirement for the tissue culture technique for filling the gap in the demand for the cell lines and the raw materials. The information regarding the *in-vitro* development of *Barleria* is very much limited.

It is seen that when nodal explants of *B. prionitis* cultured in the nutrient medium having 0.4 ppm thidiazuron (TDZ) along with 1.5 ppm BAP showed best results in inducing the shoot development and the subculturing multiplication media having 5 ppm 6-benzylaminopurine (BAP) along with 2 ppm α -naphthaleneacetic acid (NAA) showed good proliferation capacity (85). Another study also revealed that nodal explants were grown on the MS media supplemented with 1.5 ppm BAP with 0.4 ppm TDZ showed highest number of shoots and highest mean shoot length (86). Nodal explants having axillary buds were used as explants for the shoot induction and bud break in *B. prionitis*. It is seen that MS media supplemented with BAP at 8.88 µM concentration showed best results. It is seen that BAP at 4.44 µM concentration showed best multiplication efficiency (87). BAP at 1.5 ppm along with NAA at 1 ppm concentration showed best response in the development of shoot from the shoot tip explant in *B. prionitis* (88). MS media supplemented with 1 ppm BAP and 0.5 ppm TDZ showed best results with respect to the development of shoots from the nodal explants of *B. prionitis* (89).

Development of callus is important task and it helps in the establishment of cell cultures. Callus was developed from different explants of *B. prionitis*. 0.0125 ppm of 2,4-D along with Kinetin (KN) showed good results in development of callus from leaf explant and at 0.025 ppm of 2,4-D along with KN showed good results in development of callus from shoot explants (90). MS medium supplemented with 2 ppm of IAA along with BAP showed best results with respect to the leaf explants of *B. lupulina* Lindl. and developed callus was also screened for their potential medicinal properties (91). Callus was developed from the leaf explants which were cultured on the MS medium having 2 ppm of IAA along with 1.5 ppm of

BAP (92). Compact green callus was developed from the leaf explants of *B. lupulina* Lindl. It is seen that MS media having 0.1 ppm NAA along with 0.5 ppm BAP showed best response (93).

In *B. prionitis* rooting efficiency was checked under the influence of different auxin concentrations. It is seen that Indole butyric acid at 0.4 ppm concentration showed best root inducing capacity of the *in-vitro* grown shoots (86). Half strength MS media supplemented with 2.46 μ m Indole butyric acid (IBA) showed good response in rooting with good mean number and the length (87). 0.5 ppm of IBA supplemented in the half strength MS media showed best results in development of roots from the *in-vitro* grown micro shoots of *B. prionitis* (89).

Conclusion

Biotechnological studies reveal that *Barleria* L. have potential drugs which help in treating chronic illness. Scientifically there are many reports which support its requirement in curing many diseases which are chronic in nature. The phytochemicals present helps to overcome different health issues like inflammation, microbial infections, diabetes, hepatic tissue related issues, cancer, arthritis, immune deficiency etc.. Most importantly the metabolites from *Barleria* are used in creating the organism infertile. So, consuming the crude extracts without proper dose and doctor concern may lead to cause different fertility related issues. So, with the present scientific evidence it is the responsibility of the scientific community to explore further medicinally important metabolites and use them for the benefit of the humankind.

Acknowledgements

Authors are thankful to the Head of the institution, CHRIST (Deemed to be University), Bengaluru for all the encouragement and support extended for carrying out the research work.

Authors' contributions

PN conceived the idea and edited the manuscript. SWN gathered the data and wrote the manuscript.

Conflict of interests

The authors declare that there is no conflict of interest.

Supplementary files

Table 1. Some important phytochemicals present in different species of *Barleria*.

Fig. 1. Molecular structure of important metabolites in the genus *Barleria*.

References

- Balkwill MJ, Balkwill K. A preliminary analysis of distribution patterns in a large, pantropical genus, *Barleria* L. (Acanthaceae). *J Biogeogr.* 1998;25(1):95–110. <https://doi.org/10.1046/j.1365-2699.1998.251120.x>
- Kumari R, Kumar S, Kumar A, Goel KK, Dubey RC. Antibacterial, antioxidant and Immuno-modulatory properties in extracts of *Barleria lupulina* Lindl. *BMC Complement Altern Med.* 2017;17(1):1–11. <https://doi.org/10.1186/s12906-017-1989-4>
- Shendage SM, Yadav SR. Revision of the genus *Barleria* (Acanthaceae) in India. *Rheedea.* 2010;20(2):81–130.
- Khan I, Jan S, Shinwari Z, Ali M, Khan Y, Kumar T. Ethnobotany and medicinal uses of folklore medicinal plants belonging to family Acanthaceae: An updated review. *MOJ Biol Med.* 2017;1(2):34–38. <https://doi.org/10.15406/mojbm.2017.01.00009>
- Datta PC, Biswas C. Pharmacognostic study of the leaf and bark of *Barleria prionitis* Linn. *Pharm Biol.* 1968;8(4):1161–69. <https://doi.org/10.3109/13880206809083343>
- Harborne J. Scutellarein 7-rhamnosylglucoside from *Barleria prionitis*. *Phytochem Rep.* 1971;10(1):2822–23.
- Taneja SC, Tiwari HP. Structures of two iridoids from *Barleria prionitis* Linn. *Tetrahedron Lett.* 1975;24:1995–98. [https://doi.org/10.1016/S0040-4039\(00\)72344-6](https://doi.org/10.1016/S0040-4039(00)72344-6)
- Gololo SS, Bassey K, Olivier MT, Agyei NM, Shai LJ, Masoko P. Isolation of an iridoid glycoside compound from the leaves of *Barleria dinteri* collected from Zebediela sub-region in Limpopo province, South Africa. *J Pharm Sci Res.* 2017;9(8):1368–72.
- Kosmulalage KS, Zahid S, Udenigwe CC, Akhtar S, Ata A, Samarasekera R. Glutathione S-transferase, acetylcholinesterase inhibitory and antibacterial activities of chemical constituents of *Barleria prionitis*. *Zeitschrift fur Naturforsch.* 2007;62(4):580–86. <https://doi.org/10.1515/znb-2007-0417>
- Ata A, Kalhari KS, Samarasekera R. Chemical constituents of *Barleria prionitis* and their enzyme inhibitory and free radical scavenging activities. *Phytochem Lett.* 2009;2(1):37–40. <https://doi.org/10.1016/j.phytol.2008.11.005>
- Suksamrarn A. Iridoid glucosides from *Barleria lupulina*. *J Nat Prod.* 1986;49(1):179. <https://doi.org/10.1021/np50043a037>
- Byrne LT, Sasse JM, Skelton BW, Suksamrarn A, White AH. The minor iridoid glucosides of *Barleria lupulina*: Isolation, crystal structure and plant growth-inhibiting properties of 6-O-Acetylshanzhiside methyl ester. *Aust J Chem.* 1987;40(5):785–94. <https://doi.org/10.1071/CH9870785>
- Tuntiwachwuttikul P, Pancharoen O, Taylor WC. Iridoid glucosides of *Barleria lupulina*. *Phytochemistry.* 1998;49(1):163–66. [https://doi.org/10.1016/S0031-9422\(97\)01049-2](https://doi.org/10.1016/S0031-9422(97)01049-2)
- Suksamrarn S, Wongkrajang K, Kirtikara K, Suksamrarn A. Iridoid glucosides from the flowers of *Barleria lupulina*. *Planta Med.* 2003;69(9):877–79. <https://doi.org/10.1055/s-2003-43223>
- Retno W, Yasuhiro T, Tatsuro M, Suresh A, Shigetoshi K. Alkaline Phosphatase (ALP) enhancing iridoid glucosides from the Indonesian medicinal plant *Barleria lupulina*. *Nat Prod Commun.* 2010;5(1):1711–16. <https://doi.org/10.1177/1934578X1000501101>
- Kim KH, Clardy J, Senger D, Cao S. Chakylupulins A and B, two novel 4,8,8-trimethylcyclooct-2-enone derivatives from *Barleria lupulina*. *Tetrahedron Lett.* [Internet]. 2015;56(21):2732–34. <https://doi.org/10.1016/j.tetlet.2015.04.023>
- Senger DR, Hoang M V, Kim KH, Li C, Cao S. Anti-inflammatory activity of *Barleria lupulina*: Identification of active compounds that activate the Nrf2 cell defense pathway, organize cortical actin, reduce stress fibers, and improve cell junctions in microvascular endothelial cells. *J Ethnopharmacol.* [Internet]. 2016;193:397–407. <https://doi.org/10.1016/j.jep.2016.09.017>
- Kim KH, Park YJ, Chung KH, Yip MLR, Clardy J, Senger D et al. Iridoid glycosides from *Barleria lupulina*. *J Nat Prod.* 2015;78(2):320–34. <https://doi.org/10.1021/np500791a>

19. Lee SR, Clardy J, Senger DR, Cao S, Kim KH. Iridoid and phenylethanoid glycosides from the aerial part of *Barleria lupulina*. Brazilian J Pharmacogn [Internet]. 2016;26(3):281–84. <https://doi.org/10.1016/j.bjpp.2016.01.002>
20. Sarmad M, Mahalakshmi Priya A, Senthil K. Chemical composition and *in-vitro* antimicrobial activity of *Barleria lupulina* essential oil. J Herbs Spices Med Plants. 2012;18(1):101–19. <https://doi.org/10.1080/10496475.2011.653711>
21. Gopalakrishnan S, Sthanusubramania N, Raman PV. Chemical examination of roots of *Barleria buxifolia* Linn. structure of Barleriaquinone. Chem Pharm Bull. [Internet]. 1984;32(10):4137–39. <https://doi.org/10.1248/cpb.32.4137>
22. Kanchanapoom T, Noiarsa P, Ruchirawat S, Kasai R, Otsuka H. Phenylethanoid and iridoid glycosides from the Thai medicinal plant, *Barleria strigosa*. Chem Pharm Bull. 2004;52(5):612–14. <https://doi.org/10.1248/cpb.52.612>
23. Prapalert W, Santiarworn D, Liawruangrath S, Liawruangrath B, Pyne SG. Two phenylethanoid glycosides, Parvifloroside A and B, isolated from *Barleria strigosa*. Chiang Mai J Sci. 2017;44(1):168–75.
24. Harraz FMH, El-Halawany AM, El Gayed SH, Abdel-Sattar E. Iridoid glycosides from *Barleria trispinosa*. Nat Prod Res. 2009;23(10):903–38. <https://doi.org/10.1080/14786410802278350>
25. Karim A, Noor AT, Malik A, Qadir MI, Choudhary MI. Barlerisides A and B, new potent superoxide scavenging phenolic glycosides from *Barleria acanthoides*. J Enzyme Inhib Med Chem. 2009;24(6):1332–35. <https://doi.org/10.3109/14756360902887046>
26. Karim A, Noor AT, Malik A. Structure of barlericin, the neolignan diglycoside from *Barleria acanthoides*. J Asian Nat Prod Res. 2010;12(8):714–18. <https://doi.org/10.1080/10286020.2010.489895>
27. Chowdhury N, Al Hasan A, Shahidullah Tareq F, Ahsan M, Zafrul Azam ATM. 4-hydroxy-trans-cinnamate derivatives and triterpene from *Barleria cristata* (Acanthaceae). Dhaka Univ J Pharm Sci. 2013;12(2):173–75. <https://doi.org/10.3329/dujps.v12i2.17623>
28. Jiang WL, Zhang SP, Zhu HB, Hou J. Effect of 8-O-acetyl shanzhiside methylester increases angiogenesis and improves functional recovery after stroke. Basic Clin Pharmacol Toxicol. 2011;108(1):21–27. <https://doi.org/10.1111/j.1742-7843.2010.00620.x>
29. Fan PC, Ma HP, Hao Y, He XR, Sun AJ, Jiang W, Li MX, Jing LL, He L, Ma J, Jia ZP. A new anti-fibrinolytic hemostatic compound 8-O-acetyl shanzhiside methylester extracted from *Lamiophlomis rotata*. J Ethnopharmacol. [Internet]. 2016;187:232–38. Available from: <http://dx.doi.org/10.1016/j.jep.2016.04.016>
30. Jiang W, Zhang S, Fu F, Zhu H, Hou J. Inhibition of nuclear factor- κ B by 6-O-acetyl shanzhiside methyl ester protects brain against injury in a rat model of ischemia and reperfusion. J Neuroinflammation. 2010;7:55. <https://doi.org/10.1186/1742-2094-7-55>
31. Kaur PK, Vasisht K, Karan M. HPTLC method for shanzhiside esters: Simultaneous quantitative analysis of barlerin, acetylbarlerin and shanzhiside methyl ester in *Barleria* species. J Chromatogr Sep Tech. 2014;05(06). <https://doi.org/10.4172/2157-7064.1000246>
32. Rajendran J, Jacob L, Kochupappy R. Development of validated analytical methods for the simultaneous estimation of biomarkers in the leaves of *Barleria cristata* and bio analysis of the selected marker in plasma. J Adv Pharm Educ Res. 2014;4(4):409–16.
33. Amutha K, Doss DVA. Identification and antimicrobial activity of saponin fraction from the leaves of *Barleria*. 2012;3(10):4040–44. [http://dx.doi.org/10.13040/IJPSR.0975-8232.3\(10\).4040-44](http://dx.doi.org/10.13040/IJPSR.0975-8232.3(10).4040-44)
34. Dheer R, Swarnkar SK, Syeed F. Chromatographic analysis of *Barleria prionitis* Linn. Res J Pharm Technol. 2019;12(8):3679–86. <https://doi.org/10.5958/0974-360X.2019.00628.0>
35. Sridharan S, Chinnagounder S. Evaluation of antimicrobial activity and GC-MS profiling of *Barleria montana*. J Pharm Res. 2012;5(5):2921–25.
36. Tamil Selvi S, Jamuna S, Thekan S, Paulsamy S. Profiling of bioactive chemical entities in *Barleria buxifolia* L. using GC-MS analysis-a significant ethno medicinal plant. J Ayurvedic Herb Med. [Internet]. 2017;3(2):63–77.
37. Chen JL, Blanc P, Stoddart CA, Bogan M, Rozhon EJ, Parkinson N, Ye Z, Cooper R, Balick M, Nanakorn W, Kernan MR. New iridoids from the medicinal plant *Barleria prionitis* with potent activity against respiratory syncytial virus. J Nat Prod. 1998;61(10):1295–97. <https://doi.org/10.1021/np9800086y>
38. Yoosook C, Panpisutchai Y, Chaichana S, Santisuk T, Reutrakul V. Evaluation of anti-HSV-2 activities of *Barleria lupulina* and *Clinacanthus nutans*. J Ethnopharmacol. 1999;67(2):179–87. [https://doi.org/10.1016/s0378-8741\(99\)00008-2](https://doi.org/10.1016/s0378-8741(99)00008-2)
39. Gupta RS, Kumar P, Dixit VP, Dobhal MP. Antifertility studies of the root extract of the *Barleria prionitis* Linn. in male albino rats with special reference to testicular cell population dynamics. J Ethnopharmacol. 2000;70(2):111–77. [https://doi.org/10.1016/s0378-8741\(99\)00150-6](https://doi.org/10.1016/s0378-8741(99)00150-6)
40. Unny R, Chauhan AK, Joshi YC, Dobhal MP, Gupta RS. A review on potentiality of medicinal plants as the source of new contraceptive principles. Phytomedicine. 2003;10(2–3):233–60. <https://doi.org/10.1078/094471103321659997>
41. Wanichacheewa S, Singtripop T, Sassa S, Sakamoto S, Mori T. Decrease in the number of sperm associated with decreased blood testosterone levels in male rats treated with extracts from seven plants consumed by natives of northern Thailand. Environ Toxicol Pharmacol. 2001;10(1–2):1–4. [https://doi.org/10.1016/s1382-6689\(00\)00071-5](https://doi.org/10.1016/s1382-6689(00)00071-5)
42. Verma PK, Sharma A, Joshi SC, Gupta RS, Dixit VP. Effect of isolated fractions of *Barleria prionitis* root methanolic extract on reproductive function of male rats: Preliminary study. Fitoterapia. 2005;76(5):428–32. <https://doi.org/10.1016/j.fitote.2005.03.007>
43. Lans C, Harper T, Georges K, Bridgewater E. Medicinal and ethnoveterinary remedies of hunters in Trinidad. BMC Complement Altern Med. 2001;1:10. <https://doi.org/10.1186/1472-6882-1-10>
44. Suba Y, Murugesan T, Kumaravelrajan R, Mandal SC, Saha BP. Antiinflammatory, analgesic and antiperoxidative efficacy of *Barleria lupulina* Lindl. extract. Phyther Res. 2005;19(8):695–95. <https://doi.org/10.1002/ptr.1734>
45. Wanikiat P, Panthong A, Sujayanon P, Yoosook C, Rossi AG, Reutrakul V. The anti-inflammatory effects and the inhibition of neutrophil responsiveness by *Barleria lupulina* and *Clinacanthus nutans* extracts. J Ethnopharmacol. 2008;116(2):234–44. <https://doi.org/10.1016/j.jep.2007.11.035>
46. Singh B, Bani S, Gupta DK, Chandan BK, Kaul A. Anti-inflammatory activity of “TAF” an active fraction from the plant *Barleria prionitis* Linn. J Ethnopharmacol. 2003;85(2–3):187–93. [https://doi.org/10.1016/s0378-8741\(02\)00358-6](https://doi.org/10.1016/s0378-8741(02)00358-6)
47. Maji AK, Bhadra S, Mahapatra S, Banerji P, Banerjee D. Mast cell stabilization and membrane protection activity of *Barleria prionitis* L. Pharmacogn J. [Internet]. 2011;3(24):67–71. <https://doi.org/10.5530/pj.2011.24.13>
48. Singh K, Kaur R, Singh S, Bajwa BS, Prasad DN. Anti-inflammatory activity of *Barleria prionitis* Linn. J Nat Remedies. 2013;13(1):1–3.
49. Ghule B V., Kotagale NR, Patil KS. Inhibition of the pro-inflammatory mediators in rat neutrophils by shanzhiside methyl ester and its acetyl derivative isolated from *Barleria prionitis*. J Ethnopharmacol. [Internet]. 2020;249:112374. <https://doi.org/10.1016/j.jep.2019.112374>
50. Juvekar A, Gambhire M, Wankhede S. Antiinflammatory activity of aqueous extract of *Barleria cristata* leaves. J Young Pharm. 2009;1(3):220–24. <https://doi.org/10.4103/0975-1483.57068>
51. Mazumder PM, Sasmal D, Choudhary RK. Wound healing potential of the leaf extracts of *Barleria cuspidata* Heyne ex Nees. Pharmacologyonline. 2009;1:357–62.
52. Sridharan S, Meena V, Kavitha J, Brindha P, Sasikumar C.

- Barleria montana* wight and nees – a promising natural anti-inflammatory agent against formalin induced inflammation. *Int J Pharm Pharm Sci.* 2015;7(9):80–84.
53. Suba V, Murugesan T, Rao RB, Pal M, Mandal SC, Saha BP. Neuropharmacological profile of *Barleria lupulina* Lindl. extract in animal models. *J Ethnopharmacol.* 2002;81(2):251–55. [https://doi.org/10.1016/s0378-8741\(02\)00087-9](https://doi.org/10.1016/s0378-8741(02)00087-9)
 54. Amoo SO, Ndhkala AR, Finnie JF, Van Staden J. Antifungal, acetylcholinesterase inhibition, antioxidant and phytochemical properties of three *Barleria* species. *South African J Bot.* [Internet]. 2011;77(2):435–45. <https://doi.org/10.1016/j.sajb.2010.11.002>
 55. Atif M, Rahman SA, Ahmed MI, Mahmood SB, Azharuddin M. Anticataract potential of *Barleria prionitis*: *In vivo* study. *Int J Pharm Pharm Sci.* 2015;7(2):100–55.
 56. Sawarkar HA, Kashyap PP, Kaur CD. RBC haemolysis prevention and antioxidant activity of *Barleria prionitis*. *Chiang Mai J Sci.* 2018;45(2):888–96.
 57. Yadav SA, Raj AJ, Sathishkumar R. *In vitro* antioxidant activity of *Barleria noctiflora* L. f. *Asian Pac J Trop Biomed.* [Internet]. 2012;2(2 SUPPL.):S716–22. [https://doi.org/10.1016/S2221-1691\(12\)60302-5](https://doi.org/10.1016/S2221-1691(12)60302-5)
 58. Narmada R, Devaki K. *In vitro* antioxidant activity and *in vitro* α -glucosidase and α -amylase inhibitory activity of *Barleria cristata* L. *Res J Pharm Biol Chem Sci.* 2012;3(4):780–88.
 59. Tamboli F, More H. Evaluation of antiulcer and antioxidant activity of *Barleria gibsonii* Dalz. leaves. *Pharmacognosy Res.* 2016;8(4):226–30. <https://doi.org/10.4103/0974-8490.188879>
 60. Mazumder PM, Mondal A, Sasmal D, Arulmozhi S, Rathinavelusamy P. Evaluation of antiarthritic and immunomodulatory activity of *Barleria lupulina*. *Asian Pac J Trop Biomed.* [Internet]. 2012;2(3 SUPPL.):S1400–6. [https://doi.org/10.1016/S2221-1691\(12\)60425-0](https://doi.org/10.1016/S2221-1691(12)60425-0)
 61. Ghule B V., Yeole PG. *In vitro* and *in vivo* immunomodulatory activities of iridoids fraction from *Barleria prionitis* Linn. *J Ethnopharmacol.* [Internet]. 2012;141(1):424–31. <https://doi.org/10.1016/j.jep.2012.03.005>
 62. Johnson Inbaraj J, Krishna MC, Gandhidasan R, Murugesan R. Cytotoxicity, redox cycling and photodynamic action of two naturally occurring quinones. *Biochim Biophys Acta - Gen Subj.* 1999;1472(3):462–70. [https://doi.org/10.1016/s0304-4165\(99\)00150-6](https://doi.org/10.1016/s0304-4165(99)00150-6)
 63. Manglani N, Vaishnava S, Dhamodaran P, Sawarkar H. *In vitro* and *in vivo* anti-cancer activity of leaf extract of *Barleria grandiflora*. *Int J Pharm Pharm Sci.* 2014;6(3):70–72.
 64. Choudhary M, Kumar V, Gupta PK, Singh S. Anti-arthritis activity of *Barleria prionitis* Linn. leaves in acute and chronic models in Sprague Dawley rats. *Bull Fac Pharmacy, Cairo Univ.* [Internet]. 2014;52(2):199–209. <https://doi.org/10.1016/j.bfopcu.2014.07.002>
 65. Suba V, Murugesan T, Pal M, Mandal SC, Saha BP. Antiulcer activity of methanol fraction of *Barleria lupulina* Lindl. in animal models. *Phyther Res.* 2004;18(11):925–29. <https://doi.org/10.1002/ptr.1587>
 66. Jaiswal SK, Dubey MK, Das S, Rao C V. Gastroprotective effect of the iridoid fraction from *Barleria prionitis* leaves on experimentally-induced gastric ulceration. *Chin J Nat Med.* [Internet]. 2014;12(10):738–44. [https://doi.org/10.1016/S1875-5364\(14\)60113-8](https://doi.org/10.1016/S1875-5364(14)60113-8)
 67. Suba V, Murugesan T, Arunachalam G, Mandal SC, Saha BP. Anti-diabetic potential of *Barleria lupulina* extract in rats. *Phytomedicine.* 2004 [https://doi.org/10.1016/s0367-326x\(03\)00163-1](https://doi.org/10.1016/s0367-326x(03)00163-1)
 68. Dheer R, Bhatnagar P. A study of the antidiabetic activity of *Barleria prionitis* Linn. *Indian J Pharmacol.* 2010;42(2):70–73. <https://doi.org/10.4103/0253-7613.64493>
 69. Arumugam S, Natesan S. Hypoglycemic effects of *Barleria noctiflora* fractions on high fat fed with low dose Streptozotocin induced type-2 diabetes in rats. *Int J Pharm Pharm Sci.* 2016;8(2):193–200.
 70. Vasanth S, Bupesh G, Vijayakumar TS, Balachandar V, Gunasekaran DR. Evaluation of *in vitro* antidiabetic and antioxidant potential of *Barleria cristata* leaves extracts. *Asian J Pharm Clin Res.* 2018;11(4):287–90. <https://doi.org/10.22159/ajpcr.2018.v11i4.24069>
 71. Singh B, Chandan BK, Prabhakar A, Taneja SC, Singh J, Qazi GN. Chemistry and hepatoprotective activity of an active fraction from *Barleria prionitis* Linn. in experimental animals. *Phyther Res.* 2005;19(5):391–404. <https://doi.org/10.1002/ptr.1509>
 72. Banu S, Arunachalam G, Jayaveera KN, Babu VA, Kumar V. Hepatoprotective activity of methanolic extract of *Barleria montana* leaves in ethanol treated rats. *Asian Pacific J Trop Dis.* [Internet]. 2012;2(SUPPL2):S748–52. [https://doi.org/10.1016/S2222-1808\(12\)60257-6](https://doi.org/10.1016/S2222-1808(12)60257-6)
 73. Tulliballi S, Seru G. Phytochemical investigation and evaluation of hepatoprotective and antimicrobial activities on the aerial parts of *Barleria montana* (Acanthaceae). *Rasayan J Chem.* 2013;6(2):102–16.
 74. Amit K, Shiwani S, Rajesh K, Rajinder K, Singh LK, Shilpa K. Pharmacognostical, preliminary phytochemical screening and antimicrobial studies of leaves of *Barleria prionitis* Linn. *Int J Pharmacogn Phytochem Res.* 2014;6(2):369–78.
 75. Yuliasuti F, Hapsari WS, Syarifuddin A, Septianingrum NMAN, Pradani MPK. Fractionation antibiotic isolate: Trial protocol for antibiotic compound from *Barleria prionitis* L. extract. *Technol Reports Kansai Univ.* 2020;62(3):989–94.
 76. Natarajan D, Gomathi M, Yuvarajan R. Phytochemical and antibacterial evaluation of *Barleria montana* Nees. *Academic Sciences. Asian J Pharm Clin Res.* 2011;5(3):44–46.
 77. Kumari S, Jain P, Sharma B, Kadyan P, Dabur R. *In vitro* antifungal activity and probable fungicidal mechanism of aqueous extract of *Barleria grandiflora*. *Appl Biochem Biotechnol.* 2015;175(8):3571–84. <https://doi.org/10.1007/s12010-015-1527-0>
 78. Pal A, Kumar R, Upadhyay L, Tripathi YC. Antifungal activity of natural dye from aerial biomass of *Barleria prionitis* L. and dyed fabrics. *Iran J Chem Chem Eng.* 2018;37(1):213–21. <https://doi.org/10.30492/IJCCE.2018.30706>
 79. Jaiswal SK, Dubey MK, Verma AK, Das S, Vijaykumar M, Rao C V. Evaluation of iridoid glycosides from leaves of *Barleria prionitis* as an anti-diarrhoeal activity: An ethnopharmacological study. *Int J Pharm Sci.* 2010;2(3):680–86.
 80. Marya BH, Bothara SB. Investigation of antihypertensive activity of leaves of *Barleria prionitis* in doca salt induced hypersensitive rats. *Int J Pharma Sci Res.* 2013;18(2):17–19.
 81. Wang C, Gong X, Bo A, Zhang L, Zhang M, Zang E et al. Iridoids: Research advances in their phytochemistry, biological activities, and pharmacokinetics. *Molecules.* 2020;25(2):287. <https://doi.org/10.3390/molecules25020287>
 82. Devi N, Parashar B, Thakur R. Comparative, evaluation parameter for toothpaste : A Review. 2019;03(06):57–64.
 83. Kotteswari M, Krishna Rao MR, Prabhu K, Kumar S, Shil S. Antioxidant studies of one ayurvedic medicine Aswagandharishtam. *Asian J Pharm Clin Res.* 2018;11(11):227–31. <https://doi.org/10.22159/ajpcr.2018.v11i11.27593>
 84. Vador N, Vador B, Rajgor N. Anti-oxidant and anti-arthritis potential of ayurvedic formulations: Maharasnadi quath extract and Stifain tablet. *Indian J Pharm Pharmacol.* 2020;7(1):43–47. <http://doi.org/10.18231/j.ijpp.2020.009>
 85. Lone SA, Yadav AS, Badkhane Y, Sharma AK, Bakhshi SH, Raghuvanshi DK. Effect of different plant growth regulators on *in-vitro* propagation of *Barleria prionitis* L.- a threatened medicinal plant. *Int J Pharma Bio Sci.* 2011;2(1):438–44.
 86. Lone SA, Yadav AS, Bajaj A, Sharma AK, Badkhane Y, Raghuvanshi DK. Conservation strategies for threatened medicinal plant - *Barleria prionitis* L. using *in vitro* and *in vitro* propagation techniques. *Arch Phytopathol Plant Prot.* 2012;45(11):1327–40. <https://doi.org/10.1080/03235408.2012.673301>
 87. Singh R, Arya S, Arora K, Chodhury M, Dev I. Micropropagation of *Barleria prionitis* L. var. *dicantha*: an

- ethnomedicinal plant. *Adv For Sci.* 2015;2(24):73–78. <https://doi.org/10.34062/afs.v2i4.2651>
88. Kumar S, Rani A. Micropropagation of vajradanti (*Barleria prionitis* L.): a high value antidontalgic and ethno-medicinal herb. *J Phytol Res.* 2016;29:1–6.
89. Soni V, Kumari R, Swarnkar PL. High frequency *in vitro* regeneration system for conservation of *Barleria prionitis* L., a threatened medicinal shrub. *Bot Pacifica.* 2017;6(1):45–49. <https://doi.org/10.17581/bp.2017.06104>
90. Shukla P, Singh A, Gawri S AA. and SS. *In vitro* propagation of *Barleria prionitis* Linn. and its antibacterial activity. *Int J Pharma Prof Res.* 2011;2:198–200.
91. Moin S, Babu SS, Mahalakshmi Priya A. *In vitro* callus production and antibacterial activity of *Barleria lupulina* Lindl. *Asia-Pacific J Mol Biol Biotechnol.* 2012;20(2):59–64.
92. Kumari P, Yadav P, Arya A, Kumar S. *In vitro* callus production and anti-bacterial activity of *Barleria prionitis* Linn. against dental caries pathogens. *Int J Bot Res.* 2013;3(4):1–6.
93. Kumar S. Establishment of callus cultures and their Physico-Biochemical analysis in *Barleria lupulina* Lindl. *Intern Res*

Jour Managt Socio Human. 2018;9(11):244–51. <https://doi.org/10.32804/IRJMSH>

Additional information

Peer review information: *Plant Science Today* thanks Sectional Editor and the other anonymous reviewers for their contribution to the peer review of this work.

Reprints and permissions information is available at https://horizonpublishing.com/journals/index.php/PST/open_access_policy

Publisher's Note: *Horizon e-Publishing Group* remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

To cite this article: Sudheer W N, Praveen N. Phytochemical, pharmacological and tissue culture studies of some important species of genus *Barleria* L. (Acanthaceae) - a review. *Plant Science Today.* 2021;8(3):491–500. <https://doi.org/10.14719/pst.2021.8.3.1117>

Plant Science Today, published by *Horizon e-Publishing Group*, is covered by Scopus, Web of Science, BIOSIS Previews, Clarivate Analytics, etc. See https://horizonpublishing.com/journals/index.php/PST/indexing_abstracting

